Global Information
회사소개 | 문의 | 비교리스트

세계의 세포 및 유전자 치료용 해동 장비 시장 : 산업 동향과 성장 예측(-2028년)

Global Cell And Gene Therapy Thawing Equipment Market - Industry Trends And Forecast To 2028

리서치사 Data Bridge Market Research Private Limited
발행일 2021년 09월 상품 코드 1036309
페이지 정보 영문
가격
US $ 4,800 ₩ 5,834,000 Web Access (Single User License) - Read Only help
DRM(디지털 저작권 관리 시스템)이 장착된 PDF 파일로 1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste, 다운로드 및 인쇄가 불가합니다.
US $ 7,000 ₩ 8,509,000 Web Access (Enterprise License) - Printable/Downloadable help
동일 기업 내 모든 분들이 공유하여 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste, 다운로드 및 인쇄가 가능합니다. 인쇄 횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.

주의 : 라이선스에 따라 자료 이용 및 인쇄 등에 제약이 있을 수 있습니다. 자세한 내용은 라이선스 설명문( )을 참고하여 주시기 바랍니다.



세계의 세포 및 유전자 치료용 해동 장비 시장 : 산업 동향과 성장 예측(-2028년) Global Cell And Gene Therapy Thawing Equipment Market - Industry Trends And Forecast To 2028
발행일 : 2021년 09월 페이지 정보 : 영문

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계의 세포 및 유전자 치료용 해동 장비 시장 규모는 예측기간 중 14.2%의 연평균 복합 성장률(CAGR)로 성장할 것으로 예측됩니다. 세포 및 유전자 치료 개발을 위한 R&D 투자 증가. 의료비 증가 등의 요인이 시장 성장을 가속하고 있습니다.

세계의 세포 및 유전자 치료용 해동 장비(Cell And Gene Therapy Thawing Equipment) 시장을 조사했으며, 시장 개요, 시장 성장 영향요인 분석, 관련 법규제, 시장 규모 추이와 예측, 모달리티·샘플·종류·용도·최종사용자·지역/주요 국가별 분석, 기업 점유율, 주요 기업 프로파일 등을 정리했습니다.

목차

제1장 서론

제2장 시장 분류

제3장 개요

제4장 프리미엄 인사이트

제5장 업스트림(Upstream) 및 다운스트림(Downstream) 프로세스에서의 해동 장비 사용

제6장 해동 장비를 사용한 세포 및 유전자 치료 워크플로우

제7장 세계의 세포 및 유전자 치료용 해동 장비 시장 : 법규제

제8장 지역 개요

제9장 시장 개요

  • 성장 촉진요인
  • 성장 억제요인
  • 시장 기회
  • 과제

제10장 COVID-19의 영향

제11장 세계의 세포 및 유전자 치료용 해동 장비 시장 : 모달리티별

  • 벤치탑
  • 휴대용

제12장 세계의 세포 및 유전자 치료용 해동 장비 시장 : 샘플별

  • 세포치료
    • CAR T CELLS
    • NK CELLS
    • MSCS
    • TILS
    • 기타
  • 유전자 치료
    • 아데노바이러스
    • 아데노 관련 바이러스
    • 렌티 바이러스
    • 종양 용해성 바이러스
    • 기타

제13장 세계의 세포 및 유전자 치료용 해동 장비 시장 : 유형별

  • 자동 해동 시스템
  • 수동 해동 시스템

제14장 세계의 세포 및 유전자 치료용 해동 장비 시장 : 용도별

  • 업스트림(Upstream) 처리
    • 자동 해동 시스템
    • 수동 해동 시스템
  • 다운스트림(Downstream) 처리
    • 자동 해동 시스템
    • 수동 해동 시스템

제15장 세계의 세포 및 유전자 치료용 해동 장비 시장 : 최종사용자별

  • 병원/진단실험실
  • 혈액은행/수혈센터
  • 연구소/학술기관
  • 바이오테크놀러지/제약 산업
  • 제대혈 은행/줄기세포 은행
  • 유전자 은행
  • 기타

제16장 세계의 세포 및 유전자 치료용 해동 장비 시장 : 유통경로별

  • 직접 입찰
  • 서드파티 유통 판매업체
  • 기타

제17장 세계의 세포 및 유전자 치료용 해동 장비 시장 : 지역별

  • 북미
  • 유럽
  • 아시아태평양
  • 남미
  • 중동 및 아프리카

제18장 세계의 세포 및 유전자 치료용 해동 장비 시장 : 기업 상황

  • 기업 점유율 분석 : 세계
  • 기업 점유율 분석 : 북미
  • 기업 점유율 분석 : 유럽
  • 기업 점유율 분석 : 아시아태평양

제19장 SWOT 분석

제20장 기업 개요

  • MERCK KGAA
  • EPPENDORF AG
  • SARTORIUS AG
  • CYTIVA
  • BARKEY
  • BOEKEL SCIENTIFIC
  • BIOLINE INDIA
  • COOK
  • GENESIS BPS
  • HELMER SCIENTIFIC INC.
  • LABCOLD
  • PLEURISTEM THERAPEUTICS INC.
  • SARSTEDT AG & CO. KG

제21장 설문조사

제22장 관련 보고서

LSH 21.11.23

LIST OF FIGURES

  • FIGURE 1 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: SEGMENTATION 38
  • FIGURE 2 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: DATA TRIANGULATION 41
  • FIGURE 3 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: DROC ANALYSIS 42
  • FIGURE 4 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS 43
  • FIGURE 5 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: COMPANY RESEARCH ANALYSIS 43
  • FIGURE 6 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: MULTIVARIATE MODELLING 44
  • FIGURE 7 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: INTERVIEW DEMOGRAPHICS 46
  • FIGURE 8 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: DBMR MARKET POSITION GRID 47
  • FIGURE 9 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: VENDOR SHARE ANALYSIS 48
  • FIGURE 10 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: MARKET APPLICATION COVERAGE GRID 49
  • FIGURE 11 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: SEGMENTATION 53
  • FIGURE 12 NORTH AMERICA IS EXPECTED TO DOMINATE THE GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2021 TO 2028 54
  • FIGURE 13 INCREASE IN CASES OF GENETIC DISEASES SUCH AS CARDIAC AILMENTS, CYSTIC FIBROSIS AND AIDS IS EXPECTED TO DRIVE THE GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET IN THE FORECAST PERIOD OF 2021 TO 2028 55
  • FIGURE 14 TYPE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET IN 2021 & 2028 55
  • FIGURE 15 ASIA-PACIFIC IS THE FASTEST GROWING MARKET FOR THE CELL AND GENE THERAPY THAWING EQUIPMENT MANUFACTURERS IN THE FORECAST PERIOD OF 2021 TO 2028 56
  • FIGURE 16 PESTEL ANALYSIS 57
  • FIGURE 17 PORTERS FIVE FORCES MODEL 58
  • FIGURE 18 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET 67
  • FIGURE 19 INCIDENCE OF CYSTIC FIBROSIS OBSERVED IN THE COUNTRIES 69
  • FIGURE 20 PREVALENCE OF SICKLE CELL ANEMIA IN AFRICA AND EUROPE 69
  • FIGURE 21 NEW CANCER CASES WORLDWIDE, (2018) (IN MILLION) 73
  • FIGURE 22 GLOBAL CANCER INCIDENCE (2018) 74
  • FIGURE 23 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: BY MODALITY, 2020 82
  • FIGURE 24 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: BY MODALITY, 2021-2028 (USD MILLION) 83
  • FIGURE 25 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: BY MODALITY, CAGR (2021-2028) 83
  • FIGURE 26 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: BY MODALITY, LIFELINE CURVE 84
  • FIGURE 27 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET : BY SAMPLE, 2020 88
  • FIGURE 28 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET : BY SAMPLE, 2021-2028 (USD MILLION) 89
  • FIGURE 29 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET : BY SAMPLE, CAGR (2021-2028) 89
  • FIGURE 30 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: BY SAMPLE, LIFELINE CURVE 90
  • FIGURE 31 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET : BY TYPE, 2020 96
  • FIGURE 32 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET : BY TYPE, 2021-2028 (USD MILLION) 97
  • FIGURE 33 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET : BY TYPE, CAGR (2021-2028) 97
  • FIGURE 34 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: BY TYPE, LIFELINE CURVE 98
  • FIGURE 35 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: BY APPLICATION, 2020 102
  • FIGURE 36 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: BY APPLICATION, 2021-2028 (USD MILLION) 103
  • FIGURE 37 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: BY APPLICATION, CAGR (2021-2028) 103
  • FIGURE 38 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: BY APPLICATION, LIFELINE CURVE 104
  • FIGURE 39 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: BY END USER, 2020 108
  • FIGURE 40 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: BY END USER, 2021-2028 (USD MILLION) 109
  • FIGURE 41 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: BY END USER, CAGR (2021-2028) 109
  • FIGURE 42 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: BY END USER, LIFELINE CURVE 110
  • FIGURE 43 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: BY DISTRIBUTION CHANNEL, 2020 119
  • FIGURE 44 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION) 120
  • FIGURE 45 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028) 120
  • FIGURE 46 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 121
  • FIGURE 47 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: SNAPSHOT (2020) 126
  • FIGURE 48 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: BY REGION (2020) 127
  • FIGURE 49 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: BY REGION (2021 & 2028) 127
  • FIGURE 50 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: BY REGION (2020 & 2028) 128
  • FIGURE 51 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: BY MODALITY (2021-2028) 128
  • FIGURE 52 NORTH AMERICA CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: SNAPSHOT (2020) 131
  • FIGURE 53 NORTH AMERICA CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: BY COUNTRY (2020) 132
  • FIGURE 54 NORTH AMERICA CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: BY COUNTRY (2021 & 2028) 132
  • FIGURE 55 NORTH AMERICA CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: BY COUNTRY (2020 & 2028) 133
  • FIGURE 56 NORTH AMERICA CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: BY MODALITY (2021-2028) 133
  • FIGURE 57 EUROPE CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: SNAPSHOT (2020) 147
  • FIGURE 58 EUROPE CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: BY COUNTRY (2020) 148
  • FIGURE 59 EUROPE CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: BY COUNTRY (2021 & 2028) 148
  • FIGURE 60 EUROPE CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: BY COUNTRY (2020 & 2028) 149
  • FIGURE 61 EUROPE CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: BY MODALITY (2021-2028) 149
  • FIGURE 62 ASIA-PACIFIC CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: SNAPSHOT (2020) 188
  • FIGURE 63 ASIA-PACIFIC CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: BY COUNTRY (2020) 189
  • FIGURE 64 ASIA-PACIFIC CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: BY COUNTRY (2021 & 2028) 189
  • FIGURE 65 ASIA-PACIFIC CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: BY COUNTRY (2020 & 2028) 190
  • FIGURE 66 ASIA-PACIFIC CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: BY MODALITY (2021-2028) 190
  • FIGURE 67 SOUTH AMERICA CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: SNAPSHOT (2020) 226
  • FIGURE 68 SOUTH AMERICA CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: BY COUNTRY (2020) 227
  • FIGURE 69 SOUTH AMERICA CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: BY COUNTRY (2021 & 2028) 227
  • FIGURE 70 SOUTH AMERICA CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: BY COUNTRY (2020 & 2028) 228
  • FIGURE 71 SOUTH AMERICA CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: BY MODALITY (2021-2028) 228
  • FIGURE 72 MIDDLE EAST AND AFRICA CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: SNAPSHOT (2020) 240
  • FIGURE 73 MIDDLE EAST AND AFRICA CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: BY COUNTRY (2020) 241
  • FIGURE 74 MIDDLE EAST AND AFRICA CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: BY COUNTRY (2021 & 2028) 241
  • FIGURE 75 MIDDLE EAST AND AFRICA CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: BY COUNTRY (2020 & 2028) 242
  • FIGURE 76 MIDDLE EAST AND AFRICA CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: BY MODALITY (2021-2028) 242
  • FIGURE 77 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENTMARKET: COMPANY SHARE 2020 (%) 262
  • FIGURE 78 NORTH AMERICA CELL AND GENE THERAPY THAWING EQUIPMENTMARKET: COMPANY SHARE 2020 (%) 263
  • FIGURE 79 EUROPE CELL AND GENE THERAPY THAWING EQUIPMENTMARKET: COMPANY SHARE 2020 (%) 264
  • FIGURE 80 ASIA-PACIFIC CELL AND GENE THERAPY THAWING EQUIPMENTMARKET: COMPANY SHARE 2020 (%) 265
  • FIGURE 81 COMPANY SHARE ANALYSIS 268
  • FIGURE 82 COMPANY SHARE ANALYSIS 271
  • FIGURE 83 COMPANY SHARE ANALYSIS 274
  • FIGURE 84 COMPANY SHARE ANALYSIS 276

Global cell and gene therapy thawing equipment market is projected to register a CAGR of 14.2% in the forecast period of 2021 to 2028. The new market report contains data for the historic year 2019, the base year of calculation is 2020 and the forecast period is 2021 to 2028

Market Segmentation:

Global Cell and Gene Therapy Thawing Equipment Market, By Modality (Benchtop and Portable), Sample (Cell Therapies and Gene Therapies), Type (Manual Thawing System and Automatic Thawing System), Application (Upstream Processing and Downstream Processing), End User (Blood Banks And Transfusion Centres, Hospitals and Diagnostic Laboratories, Research Laboratories And Academic Institutes, Biotechnology and Pharmaceutical Industry, Cord Blood and Stem Cell Banks, Gene Banks and Others), Distribution Channel (Direct Tender, Third Part Distributor and Others), Country (U.S., Canada, Mexico, U.K., Germany, France, Spain, Italy, Netherlands, Switzerland, Russia, Belgium, Turkey, Ireland, Rest of Europe, China, South Korea, Japan, India, Australia, Singapore, Malaysia, Indonesia, Thailand, Philippines, Rest of Asia-Pacific, South Africa, Saudi Arabia, U.A.E., Egypt, Israel and Rest of Middle East and Africa, Brazil, Argentina and Rest of South America) Industry Trends and Forecast to 2028

Some of the major factors contributing to the growth of the global cell and gene therapy thawing equipment market are:

  • Rise in investment in research and development for development of cell and gene therapies
  • Rising healthcare expenditure

Market Players:

The key market players for global cell and gene therapy thawing equipment market are listed below:

  • Pluristem Therapeutics Inc.
  • Genesis BPS
  • Eppendorf AG
  • Cytiva (A subsidiary of Danaher Corporation)
  • Glenmark Pharmaceutical Inc.
  • USA (A subsidiary of Glenmark)
  • EDGE pharma
  • Cook
  • SARSTEDT AG & Co. KG
  • Barkey
  • Boekel Scientific
  • LABCOLD
  • Sartorious AG
  • Helmer Scientific Inc.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 OBJECTIVES OF THE STUDY
  • 1.2 MARKET DEFINITION
  • 1.3 OVERVIEW OF GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET
  • 1.4 LIMITATIONS
  • 1.5 MARKETS COVERED

2 MARKET SEGMENTATION

  • 2.1 MARKETS COVERED
  • 2.2 GEOGRAPHICAL SCOPE
  • 2.3 YEARS CONSIDERED FOR THE STUDY
  • 2.4 CURRENCY AND PRICING
  • 2.5 DBMR TRIPOD DATA VALIDATION MODEL
  • 2.6 MULTIVARIATE MODELLING
  • 2.7 TYPE LIFELINE CURVE
  • 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
  • 2.9 DBMR MARKET POSITION GRID
  • 2.10 VENDOR SHARE ANALYSIS
  • 2.11 MARKET APPLICATION COVERAGE GRID
  • 2.12 SECONDARY SOURCES
  • 2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

5 USAGE OF THAWING EQUIPMENT IN UPSTREAM AND DOWNSTREAM PROCESSES

  • 5.1 UPSTREAM PROCESS
  • 5.2 DOWNSTREAM PROCESS

6 CELL AND GENE THERAPY WORKFLOW USING THAWING EQUIPMENT

7 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: REGULATIONS

  • 7.1 CANADA
  • 7.2 THE U.S.
  • 7.3 EUROPE
  • 7.4 GENE THERAPY LEGISLATION IN AUSTRIA
  • 7.5 GENE THERAPY LEGISLATION IN BULGARIA
  • 7.6 JAPAN
  • 7.7 ITALY
  • 7.8 MALAYSIA

8 REGIONAL SUMMARY

9 MARKET OVERVIEW

  • 9.1 DRIVERS
    • 9.1.1 INCREASE IN CASES OF GENETIC DISEASES SUCH AS CYSTIC FIBROSIS AND SICKLE CELL ANEMIA
    • 9.1.2 RISE IN INVESTMENT IN R&D FOR DEVELOPMENT OF CELL AND GENE THERAPIES
    • 9.1.3 GOVERNMENT INITIATIVES FOR INITIATION OF CELL AND GENE THERAPY FIELD
    • 9.1.4 INCREASED IMPLEMENTATION OF ADENO-ASSOCIATED VIRUS
    • 9.1.5 TECHNOLOGICAL ADVANCEMENTS IN THE THAWING SYSTEMS
  • 9.2 RESTRAINTS
    • 9.2.1 RISE IN COST ASSOCIATED WITH CELL AND GENE THERAPY ENGINEERING
    • 9.2.2 RISE OF UNWANTED MUTAGENS
    • 9.2.3 TECHNICAL HINDRANCE FACED IN USING THAWING INSTRUMENTS
    • 9.2.4 STRICT REGULATORY FRAMEWORK
  • 9.3 OPPORTUNITIES
    • 9.3.1 INCREASING PREVALENCE OF CANCER
    • 9.3.2 STRATEGIC INITIATIVES BY MARKET PLAYERS
    • 9.3.3 RISE IN EXPENDITURE IN HEALTHCARE SECTOR
  • 9.4 CHALLENGES
    • 9.4.1 LONG APPROVAL TIME FOR IMMUNOTHERAPIES
    • 9.4.2 LACK OF ACCESSIBILITY

10 IMPACT OF COVID-19 ON GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET

  • 10.1 IMPACT ON PRICE
  • 10.2 IMPACT ON DEMAND
  • 10.3 IMPACT ON SUPPLY CHAIN
  • 10.4 STRATEGIC DECISION FOR MANUFACTURERS
  • 10.5 CONCLUSION

11 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET, BY MODALITY

  • 11.1 OVERVIEW
  • 11.2 BENCH TOP
  • 11.3 PORTABLE

12 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET, BY SAMPLE

  • 12.1 OVERVIEW
  • 12.2 CELL THERAPIES
    • 12.2.1 CAR T CELLS
    • 12.2.2 NK CELLS
    • 12.2.3 MSCS
    • 12.2.4 TILS
    • 12.2.5 OTHERS
  • 12.3 GENE THERAPIES
    • 12.3.1 ADENOVIRUS
    • 12.3.2 ADENO-ASSOCIATED VIRUSES
    • 12.3.3 LENTIVIRUSES
    • 12.3.4 ONCOLYTIC VIRUSES
    • 12.3.5 OTHERS

13 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET, BY TYPE

  • 13.1 OVERVIEW
  • 13.2 AUTOMATIC THAWING SYSTEM
  • 13.3 MANUAL THAWING SYSTEM

14 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET, BY APPLICATION

  • 14.1 OVERVIEW
  • 14.2 UPSTREAM PROCESSING
    • 14.2.1 AUTOMATIC THAWING SYSTEM
    • 14.2.2 MANUAL THAWING SYSTEM
  • 14.3 DOWNSTREAM PROCESSING
    • 14.3.1 AUTOMATIC THAWING SYSTEM
    • 14.3.2 MANUAL THAWING SYSTEM

15 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET, BY END USER

  • 15.1 OVERVIEW
  • 15.2 HOSPITALS AND DIAGNOSTIC LABORATORIES
  • 15.3 BLOOD BANKS AND TRANSFUSION CENTERS
  • 15.4 RESEARCH LABORATORIES AND ACADEMIC INSTITUTES
  • 15.5 BIOTECHNOLOGY AND PHARMACEUTICAL INDUSTRY
  • 15.6 CORD BLOOD AND STEM CELL BANKS
  • 15.7 GENE BANKS
  • 15.8 OTHERS

16 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET, BY DISTRIBUTION CHANNEL

  • 16.1 OVERVIEW
  • 16.2 DIRECT TENDER
  • 16.3 THIRD PARTY DISTRIBUTORS
  • 16.4 OTHERS

17 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET, BY REGION

  • 17.1 OVERVIEW
  • 17.2 NORTH AMERICA
    • 17.2.1 U.S.
    • 17.2.2 CANADA
    • 17.2.3 MEXICO
  • 17.3 EUROPE
    • 17.3.1 GERMANY
    • 17.3.2 FRANCE
    • 17.3.3 U.K.
    • 17.3.4 ITALY
    • 17.3.5 SPAIN
    • 17.3.6 RUSSIA
    • 17.3.7 TURKEY
    • 17.3.8 BELGIUM
    • 17.3.9 NETHERLANDS
    • 17.3.10 SWITZERLAND
    • 17.3.11 LUXEMBOURG
    • 17.3.12 REST OF EUROPE
  • 17.4 ASIA-PACIFIC
    • 17.4.1 CHINA
    • 17.4.2 INDIA
    • 17.4.3 JAPAN
    • 17.4.4 SOUTH KOREA
    • 17.4.5 AUSTRALIA
    • 17.4.6 SINGAPORE
    • 17.4.7 THAILAND
    • 17.4.8 MALAYSIA
    • 17.4.9 INDONESIA
    • 17.4.10 PHILIPPINES
    • 17.4.11 REST OF ASIA PACIFIC
  • 17.5 SOUTH AMERICA
    • 17.5.1 BRAZIL
    • 17.5.2 ARGENTINA
    • 17.5.3 REST OF SOUTH AMERICA
  • 17.6 MIDDLE EAST AND AFRICA
    • 17.6.1 SOUTH AFRICA
    • 17.6.2 SAUDI ARABIA
    • 17.6.3 U.A.E.
    • 17.6.4 EGYPT
    • 17.6.5 ISRAEL
    • 17.6.6 REST OF MIDDLE EAST AFRICA

18 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET, COMPANY LANDSCAPE

  • 18.1 COMPANY SHARE ANALYSIS: GLOBAL
  • 18.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
  • 18.3 COMPANY SHARE ANALYSIS: EUROPE
  • 18.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC

19 SWOT ANALYSIS

20 COMPANY PROFILE

  • 20.1 MERCK KGAA
    • 20.1.1 COMPANY SNAPSHOT
    • 20.1.2 REVENUE ANALYSIS
    • 20.1.3 PRODUCT PORTFOLIO
    • 20.1.4 RECENT DEVELOPMENTS
  • 20.2 EPPENDORF AG
    • 20.2.1 COMPANY SNAPSHOT
    • 20.2.2 REVENUE ANALYSIS
    • 20.2.3 PRODUCT PORTFOLIO
    • 20.2.4 RECENT DEVELOPMENTS
  • 20.3 SARTORIUS AG
    • 20.3.1 COMPANY SNAPSHOT
    • 20.3.2 REVENUE ANALYSIS
    • 20.3.3 PRODUCT PORTFOLIO
    • 20.3.4 RECENT DEVELOPMENT
  • 20.4 CYTIVA (A SUBSIDIARY OF DANAHER CORPORATION)
    • 20.4.1 COMPANY SNAPSHOT
    • 20.4.2 REVENUE ANALYSIS
    • 20.4.3 PRODUCT PORTFOLIO
    • 20.4.4 .RECENT DEVELOPMENTS
  • 20.5 BARKEY
    • 20.5.1 COMPANY SNAPSHOT
    • 20.5.2 PRODUCT PORTFOLIO
    • 20.5.3 RECENT DEVELOPMENTS
  • 20.6 BOEKEL SCIENTIFIC
    • 20.6.1 COMPANY SNAPSHOT
    • 20.6.2 PRODUCT PORTFOLIO
    • 20.6.3 RECENT DEVELOPMENT
  • 20.7 BIOLINE INDIA
    • 20.7.1 COMPANY SNAPSHOT
    • 20.7.2 PRODUCT PORTFOLIO
    • 20.7.3 RECENT DEVELOPMENTS
  • 20.8 COOK
    • 20.8.1 COMPANY SNAPSHOT
    • 20.8.2 PRODUCT PORTFOLIO
    • 20.8.3 RECENT DEVELOPMENT
  • 20.9 GENESIS BPS
    • 20.9.1 COMPANY SNAPSHOT
    • 20.9.2 PRODUCT PORTFOLIO
    • 20.9.3 RECENT DEVELOPMENTS
  • 20.10 HELMER SCIENTIFIC INC.
    • 20.10.1 COMPANY SNAPSHOT
    • 20.10.2 PRODUCT PORTFOLIO
    • 20.10.3 RECENT DEVELOPMENTS
  • 20.11 LABCOLD
    • 20.11.1 COMPANY SNAPSHOT
    • 20.11.2 PRODUCT PORTFOLIO
    • 20.11.3 RECENT DEVELOPMENTS
  • 20.12 PLEURISTEM THERAPEUTICS INC.
    • 20.12.1 COMPANY SNAPSHOT
    • 20.12.2 REVENUE ANALYSIS
    • 20.12.3 PRODUCT PORTFOLIO
    • 20.12.4 RECENT DEVELOPMENTS
  • 20.13 SARSTEDT AG & CO. KG
    • 20.13.1 COMPANY SNAPSHOT
    • 20.13.2 PRODUCT PORTFOLIO
    • 20.13.3 RECENT DEVELOPMENTS

21 QUESTIONNAIRE

22 RELATED REPORTS

Back to Top
전화 문의
F A Q